⌘K
t
BioPharma Credit PLC noted Immunocore Holdings plc's 8 November 2024 announcement of the full prepayment of a US$50 million senior secured term loan, which was originally announced on 21 November 2022 as up to US$100 million. BioPharma Credit PLC had funded US$25 million of this loan, with Immunocore not drawing the second tranche, and subsequently received US$750,000 of a US$1.5 million prepayment fee, plus US$1,014,063 in accrued interest and prepayment fees upon final repayment.
| Date | 12 Nov 2024 |
| Time | 07:00:07 |
| Category | Miscellaneous |
| ID | 7938L |
BioPharma Credit PLC
12 November 2024
BIOPHARMA CREDIT PLC
(THE "COMPANY")
STATEMENT RE Immunocore Holdings plc
Pharmakon Advisors, LP, the investment manager of the Company, notes the announcement released 8 November 2024 by Immunocore Holdings plc ("Immunocore") regarding the prepayment in full of the US$50 million senior secured term loan, of which the Company had an investment of US$25 million. The prepayment included a US$1.5 million prepayment fee, of which the Company received US$750,000.
The Company had previously announced on 21 November 2022 an investment in a senior secured loan to Immunocore of up to US$100 million in up to two tranches. The Company had previously funded US$25 million and Immunocore did not draw the second tranche. In connection with this final repayment, the Company received US$1,014,063 of accrued interest and prepayment fees.
Enquiries:
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 509